OVERVIEW

Ipamorelin (2 mg x 10) is a synthetic growth hormone–releasing peptide (GHRP) known for its selective stimulation of growth hormone (GH) release. It works by binding to ghrelin (GHS-R1a) receptors in the pituitary gland, encouraging the body to increase endogenous GH production. Unlike some earlier GHRPs, Ipamorelin is often described in research as having a more targeted action, with comparatively minimal influence on cortisol and prolactin levels. This selectivity has made it a subject of interest in experimental studies focused on muscle recovery, tissue repair, sleep support, and body composition. The 2 mg x 10 format typically indicates a multi-vial research supply intended for structured laboratory protocols.

CJC-1295 no DAC (2 mg x 10) is a modified growth hormone–releasing hormone (GHRH) analog designed to enhance the body’s natural pulsatile release of GH. The “no DAC” version has a shorter half-life than the DAC formulation, allowing for more controlled timing of administration in research settings. By stimulating GH release through a different receptor pathway than Ipamorelin, the two compounds are often discussed as complementary in experimental contexts. Together, they are studied for their potential synergistic effects on anabolic signaling, recovery processes, and metabolic function, while remaining classified primarily for laboratory investigation rather than general medical use.